Fluorine F 18 Fluorthanatrace PET/CT in Treating Participants With Primary or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

• Status: Not yet recruiting
• Trial end date: 2020-08-01
• Target enrollment: 120
• Participant gender: Female

Summary

This trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET)/computed tomography (CT) works in treating participants ovarian, fallopian tube, or primary peritoneal cancer that is primary or has come back. Fluorine F 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET/CT uses a scanner to make detailed, computerized pictures of areas inside the body. PET/CT with Fluorine F 18 fluorthanatrace may allow more tumor cells to be found in participants with ovarian, fallopian tube, or primary peritoneal cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Fluorides; Fluorodeoxyglucose F18

Criteria

Inclusion Criteria:

1. Participants will be >/= 18 years of age

2. History of known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer (may have primary or recurrent cancer at the time of study enrollment) for women only

3. At least one lesion >/= 1.0 cm that is seen on standard imaging (e.g. computed tomography (CT), magnetic resonance image (MRI), ultrasound, fludeoxyglucose (FDG) PET/CT)

Exclusion Criteria:

1. Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential at screening.

2. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician

3. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study